Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the best medical stocks to buy according to analysts. Bristol-Myers ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q2 CY2025, but sales were flat year on year at $12.27 ...

Over the past five years, BMY's one-day stock returns following earnings announcements have been evenly split: ...